Umifenovir (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Umifenovir" in Italian language version.

refsWebsite

Global rank Italian rank

6nih.gov

4^th place

9^th place

5oadoi.org

799^th place

22^nd place

5doi.org

2^nd place

7^th place

1web.archive.org

1^st place

1who.int

195^th place

342^nd place

1fda.gov

447^th place

644^th place

1cochranelibrary.com

low place

1arbidol.org

low place

arbidol.org

[Masterlek company. Instructions for the Medical Use of Arbidol‐Manufactured 8 April 2005 by order of the Federal Supervisory Organization of Health and Welfare. http://arbidol.org/instructions‐for=arbidol.pdf%7CMasterlek 2005]

cochranelibrary.com

(EN) Arbidol for preventing and treating influenza in adults and children - Huang, L - 2015 | Cochrane Library, su cochranelibrary.com, cochranelibrary. URL consultato il 27 marzo 2020.

doi.org

dx.doi.org

Leneva IA, Russell RJ, Boriskin YS, Hay AJ, Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol, in Antiviral Res., vol. 81, n. 2, febbraio 2009, pp. 132–40, DOI:10.1016/j.antiviral.2008.10.009, PMID 19028526. URL consultato il 27 marzo 2020.
Dong L, Hu S, Gao J, Discovering drugs to treat coronavirus disease 2019 (COVID-19), in Drug Discov Ther, vol. 14, n. 1, 2020, pp. 58–60, DOI:10.5582/ddt.2020.01012, PMID 32147628. URL consultato il 27 marzo 2020.
Wang Z, Chen X, Lu Y, Chen F, Zhang W, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, in Biosci Trends, vol. 14, n. 1, marzo 2020, pp. 64–68, DOI:10.5582/bst.2020.01030, PMID 32037389. URL consultato il 27 marzo 2020.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J, Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, in J. Infect., marzo 2020, DOI:10.1016/j.jinf.2020.03.002, PMID 32171872. URL consultato il 27 marzo 2020.
Wang Z, Yang B, Li Q, Wen L, Zhang R, Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China, in Clin. Infect. Dis., marzo 2020, DOI:10.1093/cid/ciaa272, PMID 32176772. URL consultato il 27 marzo 2020.

fda.gov

(EN) Influenza (Flu) Antiviral Drugs and Related Information | FDA, su fda.gov, FDA. URL consultato il 27 marzo 2020.

nih.gov

ncbi.nlm.nih.gov

Leneva IA, Russell RJ, Boriskin YS, Hay AJ, Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol, in Antiviral Res., vol. 81, n. 2, febbraio 2009, pp. 132–40, DOI:10.1016/j.antiviral.2008.10.009, PMID 19028526. URL consultato il 27 marzo 2020.
(RU) Glushkov RG, Gus'kova TA, Krylova LIu, Nikolaeva IS, [Mechanisms of arbidole's immunomodulating action], in Vestn. Akad. Med. Nauk SSSR, n. 3, 1999, pp. 36–40, PMID 10222830.
Dong L, Hu S, Gao J, Discovering drugs to treat coronavirus disease 2019 (COVID-19), in Drug Discov Ther, vol. 14, n. 1, 2020, pp. 58–60, DOI:10.5582/ddt.2020.01012, PMID 32147628. URL consultato il 27 marzo 2020.
Wang Z, Chen X, Lu Y, Chen F, Zhang W, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, in Biosci Trends, vol. 14, n. 1, marzo 2020, pp. 64–68, DOI:10.5582/bst.2020.01030, PMID 32037389. URL consultato il 27 marzo 2020.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J, Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, in J. Infect., marzo 2020, DOI:10.1016/j.jinf.2020.03.002, PMID 32171872. URL consultato il 27 marzo 2020.
Wang Z, Yang B, Li Q, Wen L, Zhang R, Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China, in Clin. Infect. Dis., marzo 2020, DOI:10.1093/cid/ciaa272, PMID 32176772. URL consultato il 27 marzo 2020.

oadoi.org

Leneva IA, Russell RJ, Boriskin YS, Hay AJ, Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol, in Antiviral Res., vol. 81, n. 2, febbraio 2009, pp. 132–40, DOI:10.1016/j.antiviral.2008.10.009, PMID 19028526. URL consultato il 27 marzo 2020.
Dong L, Hu S, Gao J, Discovering drugs to treat coronavirus disease 2019 (COVID-19), in Drug Discov Ther, vol. 14, n. 1, 2020, pp. 58–60, DOI:10.5582/ddt.2020.01012, PMID 32147628. URL consultato il 27 marzo 2020.
Wang Z, Chen X, Lu Y, Chen F, Zhang W, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, in Biosci Trends, vol. 14, n. 1, marzo 2020, pp. 64–68, DOI:10.5582/bst.2020.01030, PMID 32037389. URL consultato il 27 marzo 2020.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J, Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, in J. Infect., marzo 2020, DOI:10.1016/j.jinf.2020.03.002, PMID 32171872. URL consultato il 27 marzo 2020.
Wang Z, Yang B, Li Q, Wen L, Zhang R, Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China, in Clin. Infect. Dis., marzo 2020, DOI:10.1093/cid/ciaa272, PMID 32176772. URL consultato il 27 marzo 2020.

web.archive.org

(RU) Full Prescribing Information: Arbidol® (umifenovir) film-coated tablets 50 and 100 mg: Corrections and Additions, su State Register of Medicines, Open joint-stock company “Pharmstandard-Tomskchempharm”. URL consultato il 3 giugno 2015 (archiviato dall'url originale il 27 marzo 2020).

who.int

apps.who.int

(EN) apps.who.int (PDF), WHO, 2011. URL consultato il 27 marzo 2020.